晚期乳腺癌血管内皮细胞生长因子水平的研究  

Sduty on the level of vascular endozhelial growth factor in the peripheral blood of advanced breast carcinoma patients

作　　者：孙艳丽[1] 王立波[1] 杨光[1] 

机构地区：[1]吉林省肿瘤医院,吉林长春130021

出　　处：《中国妇幼保健》2010年第32期4695-4696,共2页Maternal and Child Health Care of China

摘　　要：目的:分析晚期乳腺癌患者治疗前后外周血中血管内皮细胞生长因子(VEGF)的变化,探讨VEGF在乳腺癌中的应用价值。方法:采用恩度联合多西紫杉醇及卡培他滨方案(治疗组)及多西紫杉醇联合卡培他滨方案(对照组)治疗晚期乳腺癌55例,ELISA(酶联免疫吸附实验)检测治疗前后外周血VEGF的水平。结果:治疗组临床有效率(RR)为63.3%(19/30),对照组为44.0%(11/25),差异无统计学意义(P>0.05);治疗组临床受益率(CBR)为80.0%(24/30),对照组为56.0%(14/25),差异有统计学意义(P<0.05)。治疗组的患者治疗前后血清VEGF水平显著下降,差异有统计学意义(P<0.01);对照组的患者治疗前后血清VEGF水平下降,但对比差异无统计学意义(P>0.05)。结论:恩度与化疗联合治疗晚期乳腺癌优于单纯化疗,VEGF是一个较好预测乳腺癌疗效的指标。Objective：To investigate the changes and clinical value of vascular endozhelial growth factor（VEGF） in the peripheral blood of advanced breast carcinoma patients.Methods：Fivty-five advanced breast carcinoma were roandomly divided into treatment group with endostar plus chemotherapy agents and control group with chemotherapy agents alone.The level of VEGF in the peripheral blood was measured by ELISA.Results：The response rate was 63.3% in treatment group and 44.0% in control group（P〉0.05）.The clinical benefit rates were 80.0% in treatment group and 56.0% in control group（P〈0.05）.The patients in treatment group had a remarkable decrease in the number of VEGF（P〈0.05） while the patients in control group had a little decrease（P〉0.05）Conclusion：Chemotherapy combined with endostar is better than chemotherapy alone in treatment of advanced breast carcinoma.VEGF,as a biomarker,may be useful in predicting the efficacy of the combined treatment.

关 键 词：晚期乳腺癌 血管内皮细胞生长因子 重组人血管内皮抑素 多西紫杉醇 卡培他滨 

分 类 号：R737.9[医药卫生—肿瘤]